Dr. Angelos M. Stergiou, CEO & Chairman of Sellas Life Sciences Group, has held international positions of increasing responsibility in pharma and biotechnology companies as well as Clinical Research Organizations over the past 14 years. He has worked in the United States and Europe in pharma and biotechnology companies including PAION AG, Accentia Biopharmaceuticals, BioVest International, Analytica International and Anavex Life Sciences. He also founded, and subsequently sold, a boutique NY-based health economics and pricing-reimbursement and health access company, Genesis Life Sciences, and performed work for big pharma.
Angelos holds a Doctor of Medicine degree and is a graduate of Kentucky Wesleyan (USA) and has done elective clinical work in interventional cardiology at the General Hospital Hagen (Germany) and cardiac surgery work at the University of Cologne (Germany) and is a Fellow of the Royal Society of Medicine (UK). He is fluent in German, Greek and English.
He has held specific roles ranging from Medical Director to Head of Clinical Research and Vice President of Product Development, Chief Medical Officer and Chief Operations Officer with responsibility for medical affairs, clinical research and development, pharmacovigilance, clinical operations, project management, regulatory affairs, biostatistics and chemistry, manufacturing and controls (CMC).
Angelos has led and overseen research endeavors in all Phases of clinical development across many indications, including CNS, cardiovascular, oncology, respiratory and autoimmune diseases, and has a broad understanding of all aspects of clinical development and medical affairs. Angelos has designed and implemented research projects in the United States, Canada, Australia, Japan and Europe. He has had numerous interactions with the FDA, EMEA and EU health authorities in addition to regulatory exposure in Australia and Japan.
Angelos was part of senior management placing one company on the German DAX as well as one company on the NASDAQ and has successfully completed M&As as well as license-deals. He also lead the development of a therapeutic cancer vaccine currently under review for approval in Europe of which he holds a patent. He has collaborated with most of the US and European investment banks as well as VC and institutional groups.
He has collaborated with the most internationally renowned academic institutions on clinical research endeavors including Beth Israel Deaconess Medical Center, MD Anderson Cancer Center, University of Pennsylvania, Cleveland Clinic, New York University, University of Heidelberg and the Mayo Clinic.
He is an active member of the World Medical Association, the American Academy of Pharmaceutical Physicians and Investigators, the Association of Clinical Research Professionals and the International Society for Pharmacoeconomics and Outcomes Research. Angelos has published papers in peer-reviewed literature and authored articles in journals in addition to being a reviewer of peer-reviewed clinical journals. A frequent guest lecturer/speaker for global clinical development and clinical research and regulatory matters, he has presented to audiences at conferences and at post-secondary institutions including Columbia University, and numerous European universities.